Effectiveness and Safety of Paclitaxel-Coated Balloon Angioplasty for Coronary Small Vessel Disease: A Prospective, Multicenter, Randomized Clinical Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effectiveness and Safety of Paclitaxel-Coated Balloon Angioplasty for Coronary Small Vessel Disease: A Prospective, Multicenter, Randomized Clinical Study

  • By

  • Mingduo Zhang

  • Shiqi Liu

  • Zhao Ma

  • Meichen Sun

  • Yifei Nie

  • Baoen Zhang

  • Min Zhang

  • Xiantao Song

  • Dongfeng Zhang

  • March 12, 2026

Share

  • 1

    This study evaluates the efficacy and safety of a paclitaxel-coated balloon for treating coronary small vessel disease.

  • 2

    Patients with reference vessel diameters between 1.50 mm and 2.50 mm were included in this multicenter, randomized controlled trial.

  • 3

    The study aims to compare in-lesion late lumen loss at 9 months between the paclitaxel-coated balloon and a control group.

  • 4

    Inclusion criteria required patients to have stable or unstable angina, NSTEMI, or STEMI beyond one week.

  • 5

    Exclusion criteria included recent STEMI, significant hematologic abnormalities, and severe comorbid conditions.

Original Source(s)

Effectiveness and Safety of Paclitaxel-Coated Balloon Angioplasty for Coronary Small Vessel Disease: A Prospective, Multicenter, Randomized Clinical Study

  • by Mingduo Zhang, Shiqi Liu, Zhao Ma, Meichen Sun, Yifei Nie, Baoen Zhang, Min Zhang, Xiantao Song, Dongfeng Zhang

  • March 12, 2026

Related Content

Does Weight Loss Intervention Improve Persistent AF?

Randomized trial found significant weight loss did not improve atrial fibrillation severity or burden in older patients with persistent disease.

Consensus Panel Calls for Enhanced Radiation Shielding

A consensus statement called for immediate adoption of enhanced radiation protection devices, although evidence of long-term health benefits and effectiveness across procedural settings remains limited.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.